• 作者：Luis Vida Pé ; rez ; ^{lvp80@hotmail.com} ; Federico Gó ; mez Camacho ; Valle Garcí ; a Sá ; nchez ; Eva M.a Iglesias Flores ; Laura Castillo Molina ; Antonio Cerezo Ruiz ; Luis Casá ; is Juanena ; Juan Francisco De Dios Vega
• 关键词：Virus de la hepatitis B ; Enfermedad inflamatoria intestinal ; Vacuna
• 刊名：Medicina Cl¨ªnica
• 出版年：2009
• 出版时间：14 March 2009
• 年：2009
• 卷：132
• 期：9
• 页码：331-335
• 全文大小：131 K

Background and objective

Patients with Inflammatory Bowel Disease (IBD) may have an increased risk of developing hepatitis B virus (HB) infection. Invasive procedures such as colonoscopies and surgery might be some of the reasons for this. Moreover, the use of immunosuppressors may reactivate a latent infection. We assessed the immune status among IBD patients receiving HB vaccine and the circumstances that predicted its results.

Aims and methods

Serological markers of B and C hepatitis virus in patients with IBD who were referred for consultation were assessed since 2006. The subsequent determination of antibodies against superficial antigen (HBsAb) could differentiate between responders and non responders to the vaccine and an adequate immunity to HB was defined as higher than 10 mUI/ml.

Results

One hundred and twenty nine patients were included in our study. Fifty-six (43,4 % ) patients had received immunosuppressive medication before the first vaccine dose. Notably, 85 (65.9 % ) patients had inadequate levels of HBsAb: 36 had no detectable levels and 49 had less than 10 mUI/ml. Younger patients had a better immunity response than older patients (30.91¡À14.8 vs 39.91¡À14.2) (p<0.001).

Conclusion

More than half of the patients had a suboptimal serologic response after vaccination. Only the younger group showed a better rate of response. It was not demonstrated whether an additional fourth dose of vaccination or a complete revaccination improved the rate of responders.